查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
学名药受託製造市场规模·占有率·趋势分析 (2022-2030年):医药品类型·产品·给药途径·各用途
市场调查报告书
商品编码
1170949

学名药受託製造市场规模·占有率·趋势分析 (2022-2030年):医药品类型·产品·给药途径·各用途

Generic Pharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis Report By Drug Type (Branded, Unbranded), By Product (API, Drug Product), By Route Of Administration, By Application, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

全球学名药受託製造的市场规模在2022年到2030年间预计将以年复合成长率5.8％推移，到2030年前将达到1,069亿美元的规模成长。

伴随外包引进的降低成本和缩短时间优点是推动产业的要素。

本报告提供全球学名药受託製造的市场调查，提供市场概要，市场成长的各种影响因素分析，市场规模的转变·预测，各种区分·地区/各主要国家的详细分析，竞争环境，市场占有率，主要企业简介等资讯。

目录

第1章 调查手法·调查范围

第2章 摘要整理

第3章 学名药受託製造市场可变因素·趋势·展望

  • 市场预测
  • 普及·成长预测的製图
  • 市场动态
    • 推动市场要素的分析
    • 阻碍市场要素的分析
  • 市场分析工具
    • 波特的五力分析
    • 大环境分析
    • 主要交易·策略性联盟的分析
  • COVID-19影响·改革策略

第4章 学名药受託製造市场估计·趋势分析:各药物类型

  • 定义·范围
  • 市场占有率分析:2021年·2030年
    • 品牌非专利
    • 非品牌非专利

第5章 学名药受託製造市场估计·趋势分析:各产品

  • 定义·范围
  • 市场占有率分析:2021年·2030年
    • API
    • 医药品

第6章 学名药受託製造市场估计·趋势分析:各给药途径

  • 定义·范围
  • 市场占有率分析:2021年·2030年
    • 口服剂
    • 非口服剂
    • 局部剂
    • 其他

第7章 学名药受託製造市场估计·趋势分析:各用途

  • 定义·范围
  • 市场占有率分析:2021年·2030年
    • 肿瘤
    • 免疫
    • 糖尿病治疗
    • 神经
    • 抗凝固剂
    • 心臟血管
    • 呼吸系统
    • 疼痛
    • HIV抗病毒药物
    • 其他

第8章 学名药受託製造市场估计·趋势分析:各地区

  • 市场占有率分析:2021年·2030年
  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东·非洲

第9章 竞争分析

  • 由于主要加入企业的近几年的发展·影响分析
  • 企业/竞争上的分类
  • 参与企业的分类
  • 业者情势

第10章 竞争情形

  • 企业简介
    • Recipharm AB
    • Siegfried Holding AG
    • Aurobindo Pharma
    • Cambrex Corporation
    • Alcami Corporation, Inc.
    • Curia Global, Inc.
    • Catalent, Inc
    • Acme Generics Pvt Ltd.
    • Metric Contract Services
    • Syngene International Limited
    • Pfizer CentreOne;
Product Code: GVR-4-68039-997-7

Generic Pharmaceuticals Contract Manufacturing Market Growth & Trends:

The global generic pharmaceuticals contract manufacturing market size is expected to reach USD 106.9 billion by 2030, registering a CAGR of 5.8% over the forecast period, according to a new report by Grand View Research, Inc. Cost-saving and time-saving benefits associated with the implementation of outsourcing is responsible for driving the industry. A significant number of people globally suffer from chronic diseases. For instance, the CDC states that 6 in 10 adults in the U.S. suffer from at least one chronic disease and 4 in 10 adults suffer from two or more chronic diseases. Chronic diseases are required to be treated for a long time. The high cost of medicines is increasing the demand for cost-effective generic drugs for the treatment of chronic diseases.

This is expected to support the industry's growth post-pandemic. There is an improvement in the regulatory approval of generic drugs. For instance, in 2021, the FDA approved 93 generic drugs, and by October 2022, the regulatory authority approved over 95 generic drugs. Such improvements are expected to have a positive impact on the manufacturing of generic drugs and; thus, support the industry growth. The Japanese government is constantly trying to improve the generic pharmaceuticals market in the country. The government is also taking measures to improve the supply of generics in the country and is also encouraging medical institutes to promote the use of generic drugs.

This is expected to improve CMO activities for generics in the coming years. Global spending on medicines is also on the rise. According to the data provided in a report published by IQVIA in April 2021, global spending on medicine is expected to increase in the next 4-5 years. The report states that global spending on medicine accounted for USD 1, 265 billion in 2020 and is going to reach USD 1,580-1,610 billion by 2025. This is also expected to improve the demand for generic drugs owing to their cost efficiency, thereby supporting the industry in growth.

Generic Pharmaceuticals Contract Manufacturing Market Report Highlights:

  • The branded generics segment held the largest share in 2021due to the preference for branded generics among physicians. Some branded generic manufacturers offer benefits and gifts to physicians for boosting their product sales. This further contributes to the demand for branded generic manufacturing in the market
  • The API product segment held the largest share in 2021. The growing demand for generic drugs is supporting the demand for generic API contract manufacturing
  • The parenteral route of administration segment is expected to grow at the fastest CAGR over the forecast period due to the bioavailability of parenteral drugs over other formulations
  • The oncology segment is expected to register the fastest CAGRfrom 2022 to 2030 owing to the high cost of cancer drugs contributing to the demand for cost-effective generic medicines
  • Asia Pacific is expected to record the highest CAGR over the forecast period mainly due to the low cost of generic drug manufacturing

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Type
    • 1.1.2. Product
    • 1.1.3. Route of Administration
    • 1.1.4. Application
    • 1.1.5. Regional scope
    • 1.1.6. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Generic Pharmaceuticals Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Supportive government initiatives to improve the adoption of generic drugs
      • 3.3.1.2. Significant number of drugs losing patents
      • 3.3.1.3. Growing prevalence of chronic diseases contributing to the demand for cost-effective generics
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. Third party performance
  • 3.4. Generic pharmaceuticals contract manufacturing market Analysis Tools
    • 3.4.1. Porter's Five Forces Analysis
    • 3.4.2. PESTLE Analysis
    • 3.4.3. Major Deals & Strategic Alliances Analysis
      • 3.4.3.1. Mergers and Acquisition
      • 3.4.3.2. Expansions
      • 3.4.3.3. Agreements and Collaborations
      • 3.4.3.4. Product and Service Launches
  • 3.5. Covid-19 Impact and Reformation Strategy

Chapter 4. Generic Pharmaceuticals Contract Manufacturing Market: Drug Type Estimates & Trend Analysis

  • 4.1. Definitions and Scope
  • 4.2. Generic pharmaceuticals contract manufacturing market Share, 2021 & 2030
    • 4.2.1. Branded Generics
      • 4.2.1.1. Branded Generics market estimates and forecast 2018 to 2030 (USD Billion)
    • 4.2.2. Unbranded Generics
      • 4.2.2.1. Unbranded market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 5. Generic Pharmaceuticals Contract Manufacturing Market: Product Estimates & Trend Analysis

  • 5.1. Definitions and Scope
  • 5.2. Generic pharmaceuticals contract manufacturing market Share, 2021 & 2030
    • 5.2.1. API
      • 5.2.1.1. API market estimates and forecast 2018 to 2030 (USD Billion)
    • 5.2.2. Drug Product
      • 5.2.2.1. Drug Product market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 6. Generic Pharmaceuticals Contract Manufacturing Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Definitions and Scope
  • 6.2. Generic pharmaceuticals contract manufacturing market Share, 2021 & 2030
    • 6.2.1. Oral
      • 6.2.1.1. Oral market estimates and forecast 2018 to 2030 (USD Billion)
    • 6.2.2. Parenteral
      • 6.2.2.1. Parenteral market estimates and forecast 2018 to 2030 (USD Billion)
    • 6.2.3. Topical
      • 6.2.3.1. Topical g market estimates and forecast 2018 to 2030 (USD Billion)
    • 6.2.4. Others
      • 6.2.4.1. Others market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 7. Generic Pharmaceuticals Contract Manufacturing Market: Application Estimates & Trend Analysis

  • 7.1. Definitions and Scope
  • 7.2. Generic pharmaceuticals contract manufacturing market Share, 2021 & 2030
    • 7.2.1. Oncology
      • 7.2.1.1. Oncology market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.2. Immunology
      • 7.2.2.1. Immunology market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.3. Antidiabetic
      • 7.2.3.1. Antidiabetic market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.4. Neurology
      • 7.2.4.1. Neurology market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.5. Anticoagulants
      • 7.2.5.1. Anticoagulants market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.6. Cardiovascular
      • 7.2.6.1. Cardiovascular market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.7. Respiratory
      • 7.2.7.1. Respiratory market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.8. Pain
      • 7.2.8.1. Pain market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.9. HIV Antivirals
      • 7.2.9.1. HIV antivirals market estimates and forecast 2018 to 2030 (USD Billion)
    • 7.2.10. Others
      • 7.2.10.1. Others market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 8. Generic Pharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional market share analysis, 2021 & 2030
  • 8.2. North America
    • 8.2.1. U.S.
      • 8.2.1.1. U.S. Market estimates and forecast, 2018 - 2030
    • 8.2.2. Canada
      • 8.2.2.1. Canada Market estimates and forecast, 2018 - 2030
  • 8.3. Europe
    • 8.3.1. U.K.
      • 8.3.1.1. U.K. Market estimates and forecast, 2018 - 2030
    • 8.3.2. Germany
      • 8.3.2.1. Germany Market estimates and forecast, 2018 - 2030
    • 8.3.3. France
      • 8.3.3.1. France Market estimates and forecast, 2018 - 2030
    • 8.3.4. Italy
      • 8.3.4.1. Italy Market estimates and forecast, 2018 - 2030
    • 8.3.5. Spain
      • 8.3.5.1. Spain Market estimates and forecast, 2018 - 2030
    • 8.3.6. The Netherlands
      • 8.3.6.1. The Netherlands Market estimates and forecast, 2018 - 2030
    • 8.3.7. Sweden
      • 8.3.7.1. Sweden Market estimates and forecast, 2018 - 2030
    • 8.3.8. Switzerland
      • 8.3.8.1. Switzerland Market estimates and forecast, 2018 - 2030
    • 8.3.9. Russia
      • 8.3.9.1. Russia Market estimates and forecast, 2018 - 2030
    • 8.3.10. Belgium
      • 8.3.10.1. Belgium Market estimates and forecast, 2018 - 2030
  • 8.4. Asia Pacific
    • 8.4.1. Japan
      • 8.4.1.1. Japan Market estimates and forecast, 2018 - 2030
    • 8.4.2. China
      • 8.4.2.1. China Market estimates and forecast, 2018 - 2030
    • 8.4.3. India
      • 8.4.3.1. India Market estimates and forecast, 2018 - 2030
    • 8.4.4. Australia
      • 8.4.4.1. Australia Market estimates and forecast, 2018 - 2030
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand Market estimates and forecast, 2018 - 2030
    • 8.4.7. Malaysia
      • 8.4.7.1. Malaysia Market estimates and forecast, 2018 - 2030
    • 8.4.8. New Zealand
      • 8.4.8.1. New Zealand Market estimates and forecast, 2018 - 2030
    • 8.4.9. Philippines
      • 8.4.9.1. Philippines Market estimates and forecast, 2018 - 2030
    • 8.4.10. Singapore
      • 8.4.10.1. Singapore Market estimates and forecast, 2018 - 2030
  • 8.5. Latin America
    • 8.5.1. Brazil
      • 8.5.1.1. Brazil Market estimates and forecast, 2018 - 2030
    • 8.5.2. Mexico
      • 8.5.2.1. Mexico Market estimates and forecast, 2018 - 2030
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Market estimates and forecast, 2018 - 2030
    • 8.5.4. Colombia;
      • 8.5.4.1. Colombia Market estimates and forecast, 2018 - 2030
    • 8.5.5. Chile
      • 8.5.5.1. Chile Market estimates and forecast, 2018 - 2030
  • 8.6. MEA
    • 8.6.1. South Africa
      • 8.6.1.1. South Africa Market estimates and forecast, 2018 - 2030
    • 8.6.2. Saudi Arabia
      • 8.6.2.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
    • 8.6.3. UAE
      • 8.6.3.1. UAE Market estimates and forecast, 2018 - 2030
    • 8.6.4. Israel
      • 8.6.4.1. Israel Market estimates and forecast, 2018 - 2030
    • 8.6.5. Egypt
      • 8.6.5.1. Egypt Market estimates and forecast, 2018 - 2030

Chapter 9. Competitive Analysis

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participant
  • 9.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
  • 9.3. Participant Categorization
    • 9.3.1. Innovators
      • 9.3.1.1. Recipharm AB
      • 9.3.1.2. Siegfried Holding AG
      • 9.3.1.3. Aurobindo Pharma
  • 9.4. Vendor Landscape
    • 9.4.1. List of Key Service Providers
    • 9.4.2. Market Differentiators
    • 9.4.3. Generic pharmaceuticals contract manufacturing market Share Analysis

Chapter 10. Competitive Landscape

  • 10.1. Company Profiles
    • 10.1.1. Recipharm AB
      • 10.1.1.1. Company overview
      • 10.1.1.2. Financial performance
      • 10.1.1.3. Service benchmarking
      • 10.1.1.4. Strategic initiatives
    • 10.1.2. Siegfried Holding AG
      • 10.1.2.1. Company overview
      • 10.1.2.2. Financial performance
      • 10.1.2.3. Service benchmarking
      • 10.1.2.4. Strategic initiatives
    • 10.1.3. Aurobindo Pharma
      • 10.1.3.1. Company overview
      • 10.1.3.2. Financial performance
      • 10.1.3.3. Service benchmarking
      • 10.1.3.4. Strategic initiatives
    • 10.1.4. Cambrex Corporation
      • 10.1.4.1. Company overview
      • 10.1.4.2. Financial performance
      • 10.1.4.3. Service benchmarking
      • 10.1.4.4. Strategic initiatives
    • 10.1.5. Alcami Corporation, Inc.
      • 10.1.5.1. Company overview
      • 10.1.5.2. Financial performance
      • 10.1.5.3. Service benchmarking
      • 10.1.5.4. Strategic initiatives
    • 10.1.6. Curia Global, Inc.
      • 10.1.6.1. Company overview
      • 10.1.6.2. Financial performance
      • 10.1.6.3. Service benchmarking
      • 10.1.6.4. Strategic initiatives
    • 10.1.7. Catalent, Inc
      • 10.1.7.1. Company overview
      • 10.1.7.2. Financial performance
      • 10.1.7.3. Service benchmarking
      • 10.1.7.4. Strategic initiatives
    • 10.1.8. Acme Generics Pvt Ltd.
      • 10.1.8.1. Company overview
      • 10.1.8.2. Financial performance
      • 10.1.8.3. Service benchmarking
      • 10.1.8.4. Strategic initiatives
    • 10.1.9. Metric Contract Services
      • 10.1.9.1. Company overview
      • 10.1.9.2. Financial performance
      • 10.1.9.3. Service benchmarking
      • 10.1.9.4. Strategic initiatives
    • 10.1.10. Syngene International Limited
      • 10.1.10.1. Company overview
      • 10.1.10.2. Financial performance
      • 10.1.10.3. Service benchmarking
      • 10.1.10.4. Strategic initiatives
    • 10.1.11. Pfizer CentreOne;
      • 10.1.11.1. Company overview
      • 10.1.11.2. Financial performance
      • 10.1.11.3. Service benchmarking
      • 10.1.11.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig 1 Market research process
  • Fig 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Volume Price Analysis
  • Fig. 10 Generic pharmaceuticals contract manufacturing market snapshot (2021)
  • Fig. 11 Generic pharmaceuticals contract manufacturing market segmentation
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 Generic pharmaceuticals contract manufacturing market drug type outlook: Segment dashboard
  • Fig. 18 Generic pharmaceuticals contract manufacturing market: Drug type movement analysis
  • Fig. 19 Branded Generics market (USD Billion)
  • Fig. 20 Unbranded Generics market (USD Billion)
  • Fig. 21 Generic pharmaceuticals contract manufacturing market product outlook: Segment dashboard
  • Fig. 22 Generic pharmaceuticals contract manufacturing market: Product movement analysis
  • Fig. 23 API market (USD Billion)
  • Fig. 24 Drug Product market (USD Billion)
  • Fig. 25 Generic pharmaceuticals contract manufacturing market route of adminsitration outlook: Segment dashboard
  • Fig. 26 Generic pharmaceuticals contract manufacturing market: Route of adminsitrationmovement analysis
  • Fig. 27 Oral market (USD Billion)
  • Fig. 28 Topical market (USD Billion)
  • Fig. 29 Parentral market (USD Billion)
  • Fig. 30 Others market (USD Billion)
  • Fig. 31 Generic pharmaceuticals contract manufacturing market application outlook: Segment dashboard
  • Fig. 32 Generic pharmaceuticals contract manufacturing market: Application movement analysis
  • Fig. 33 Oncology market (USD Billion)
  • Fig. 34 Immunology market (USD Billion)
  • Fig. 35 Antidiabetic market (USD Billion)
  • Fig. 36 Neurology market (USD Billion)
  • Fig. 37 Anticoagulants market (USD Billion)
  • Fig. 38 Cardiovascular market (USD Billion)
  • Fig. 39 Respiratory market (USD Billion)
  • Fig. 40 Pain market (USD Billion)
  • Fig. 41 HIV antivirals market (USD Billion)
  • Fig. 42 Others market (USD Billion)
  • Fig. 43 Regional market: Key takeaways
  • Fig. 44 Regional outlook, 2021 & 2030
  • Fig. 45 North America market, 2018 - 2030 (USD Billion)
  • Fig. 46 U.S. market, 2018 - 2030 (USD Billion)
  • Fig. 47 Canada Market, 2018 -2030 (USD Billion)
  • Fig. 48 Europe Market, 2018 -2030 (USD Billion)
  • Fig. 49 U.K. Market, 2018 -2030 (USD Billion)
  • Fig. 50 Germany Market, 2018 -2030 (USD Billion)
  • Fig. 51 France Market, 2018 -2030 (USD Billion)
  • Fig. 52 Italy Market, 2018 -2030 (USD Billion)
  • Fig. 53 SpainMarket, 2018 -2030 (USD Billion)
  • Fig. 54 The Netherlands Market, 2018 -2030 (USD Billion)
  • Fig. 55 Switzerland Market, 2018 -2030 (USD Billion)
  • Fig. 56 Sweden Market, By Service, 2018 -2030 (USD Billion)
  • Fig. 57 Asia Pacific market, 2018 - 2030 (USD Billion)
  • Fig. 58 China market, 2018 - 2030 (USD Billion)
  • Fig. 59 India market, 2018 - 2030 (USD Billion)
  • Fig. 60 Japan market, 2018 - 2030 (USD Billion)
  • Fig. 61 Australia market, 2018 - 2030 (USD Billion)
  • Fig. 62 Malaysia market, 2018 - 2030 (USD Billion)
  • Fig. 63 Indonesia market, 2018 - 2030 (USD Billion)
  • Fig. 64 Taiwan market, 2018 - 2030 (USD Billion)
  • Fig. 65 Thailand market, 2018 - 2030 (USD Billion)
  • Fig. 66 Singapore market, 2018 - 2030 (USD Billion)
  • Fig. 67 South Korea market, 2018 - 2030 (USD Billion)
  • Fig. 68 Latin America market, 2018 - 2030 (USD Billion)
  • Fig. 69 Brazil market, 2018 - 2030 (USD Billion)
  • Fig. 70 Mexico market, 2018 - 2030 (USD Billion)
  • Fig. 71 Argentina market, 2018 - 2030 (USD Billion)
  • Fig. 72 Colombia market, 2018 - 2030 (USD Billion)
  • Fig. 73 MEA market, 2018 - 2030 (USD Billion)
  • Fig. 74 South Africa market, 2018 - 2030 (USD Billion)
  • Fig. 75 Saudi Arabia market, 2018 - 2030 (USD Billion)
  • Fig. 76 Israel market, 2018 - 2030 (USD Billion)
  • Fig. 77 UAE market, 2018 - 2030 (USD Billion)